

# Cristina Gasparetto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7905563/publications.pdf>

Version: 2024-02-01

121  
papers

1,927  
citations

257450

24  
h-index

289244

40  
g-index

121  
all docs

121  
docs citations

121  
times ranked

2534  
citing authors

#	ARTICLE	IF	CITATIONS
1	Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. <i>British Journal of Cancer</i> , 2022, 126, 718-725.	6.4	21
2	Anaplastic Multiple Myeloma: Case Series and Literature Review. , 2022, 5, 1-11.		2
3	Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect <sup>Â</sup> MM Registry. <i>British Journal of Haematology</i> , 2021, 193, 93-100.	2.5	4
4	Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 137-143.	2.4	15
5	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2021, 137, 1154-1165.	1.4	49
6	Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>EJHaem</i> , 2021, 2, 56-65.	1.0	15
7	Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 181.e1-181.e9.	1.2	18
8	Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8038-8038.	1.6	6
9	Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8018-8018.	1.6	13
10	Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8006-8006.	1.6	33
11	The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7003-7003.	1.6	2
12	Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant. <i>Blood Cancer Journal</i> , 2021, 11, 92.	6.2	2
13	Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	12
14	A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 775-784.	0.4	12
15	Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 669.e1-669.e8.	1.2	4
16	Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 784.e1-784.e7.	1.2	4
17	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 149.	6.2	5
18	Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	2

#	ARTICLE	IF	CITATIONS
19	Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect Â® Multiple Myeloma (MM) Disease Registry. <i>Blood</i> , 2021, 138, 117-117.	1.4	2
20	Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-up from a Single Center. <i>Blood</i> , 2021, 138, 1827-1827.	1.4	1
21	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1630-1642.	10.7	237
22	Clinical and Neuroimaging Correlates of Post-Transplant Delirium. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2323-2328.	2.0	0
23	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2020, 34, 3298-3309.	7.2	37
24	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	7.2	54
25	Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 8-9.	1.4	26
26	Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma. <i>Blood</i> , 2020, 136, 12-14.	1.4	4
27	Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 14-15.	1.4	9
28	Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 18-19.	1.4	11
29	Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 45-46.	1.4	4
30	Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8530-8530.	1.6	13
31	Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8518-8518.	1.6	1
32	Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2020, 136, 18-19.	1.4	0
33	Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2020, 136, 24-25.	1.4	0
34	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
35	Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade. <i>Cancer Letters</i> , 2019, 440-441, 1-10.	7.2	15
36	Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1869-1869.	1.4	36

#	ARTICLE	IF	CITATIONS
37	A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 3157-3157.	1.4	5
38	Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 141-141.	1.4	18
39	Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 3165-3165.	1.4	9
40	Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 926-926.	1.4	17
41	Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 1888-1888.	1.4	35
42	T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study. <i>Blood</i> , 2019, 134, 142-142.	1.4	25
43	Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 3145-3145.	1.4	4
44	Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8032-8032.	1.6	2
45	Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality. <i>Blood</i> , 2019, 134, 5731-5731.	1.4	0
46	Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone. <i>Blood</i> , 2019, 134, 3177-3177.	1.4	0
47	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2588-2594.	1.3	22
48	Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2018, 132, 2546-2554.	1.4	110
49	Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 480-485.e3.	0.4	27
50	The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation. <i>Cancer Medicine</i> , 2018, 7, 3257-3268.	2.8	20
51	Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 29.	17.0	36
52	Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8037-8037.	1.6	1
53	Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8041-8041.	1.6	2
54	Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. <i>Hematological Oncology</i> , 2017, 35, 752-759.	1.7	5

#	ARTICLE	IF	CITATIONS
55	Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1872-1879.	1.3	50
56	Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 424-432.	0.4	14
57	Recognition of early mortality in multiple myeloma by a prediction matrix. <i>American Journal of Hematology</i> , 2017, 92, 915-923.	4.1	31
58	Panobinostat for the management of multiple myeloma. <i>Future Oncology</i> , 2017, 13, 477-488.	2.4	42
59	Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPD) in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8008-8008.	1.6	1
60	Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8023-8023.	1.6	3
61	Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8040-8040.	1.6	1
62	Treatment outcomes and healthcare resource utilization (HRU) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with lenalidomide (LEN) only or no maintenance: Connect MM registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19527-e19527.	1.6	0
63	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. <i>Journal of Hematology and Oncology</i> , 2016, 9, 71.	17.0	20
64	Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 999-1006.	5.8	63
65	Post-Transplant Outcomes in High-Risk Compared with Nonâ€“High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
66	Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma. <i>Oncology and Therapy</i> , 2016, 4, 287-301.	2.6	6
67	Connect MMâ€™â€™ the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. <i>Leukemia and Lymphoma</i> , 2016, 57, 2228-2231.	1.3	21
68	Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2016, 128, 645-645.	1.4	46
69	Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8005-8005.	1.6	29
70	Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8032-8032.	1.6	7
71	Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. <i>Blood</i> , 2015, 126, 2284-2290.	1.4	201
72	Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 368-376.	0.4	28

#	ARTICLE	IF	CITATIONS
73	A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.. Blood, 2015, 126, 1857-1857.	1.4	1
74	Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. Blood, 2015, 126, 377-377.	1.4	6
75	A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. Blood, 2015, 126, 509-509.	1.4	27
76	Autologous Hematopoietic Cell Transplantation in Patients with High Risk Multiple Myeloma: Post-Transplant Responses Do Not Translate to Longer Survival. Blood, 2015, 126, 1979-1979.	1.4	0
77	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1796-1803.	2.0	73
78	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 257-263.	2.0	15
79	A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma. Blood, 2014, 124, 4739-4739.	1.4	2
80	A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2014, 124, 4741-4741.	1.4	15
81	Exploring variations in multiple myeloma management through in-practice research.. Journal of Clinical Oncology, 2014, 32, e19534-e19534.	1.6	1
82	Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma. Blood, 2013, 122, 1970-1970.	1.4	4
83	Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma. Blood, 2013, 122, 690-690.	1.4	30
84	Changes in patient-reported outcomes in patients diagnosed with and treated for multiple myeloma in the Connect MM registry.. Journal of Clinical Oncology, 2013, 31, 8586-8586.	1.6	1
85	Early mortality (EM) for newly diagnosed multiple myeloma (NDMM) in the Connect MM U.S. registry.. Journal of Clinical Oncology, 2013, 31, 8596-8596.	1.6	1
86	Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX); Tj ETQq0 0 0 rgt /Overd lock 10 Tf		
87	A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2012, 120, 74-74.	1.4	12
88	PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8012-8012.	1.6	1
89	Connect MM: The multiple myeloma (MM) disease registryâ€™ Incidence of second primary malignancies (SPM).. Journal of Clinical Oncology, 2012, 30, 8037-8037.	1.6	1
90	Race- and health-related quality of life among patients newly diagnosed with multiple myeloma.. Journal of Clinical Oncology, 2012, 30, e18556-e18556.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1626-1626.	1.4	0
92	Reply to A. Gratwohl. <i>Journal of Clinical Oncology</i> , 2011, 29, e484-e484.	1.6	0
93	High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation. <i>Blood</i> , 2011, 118, 2012-2012.	1.4	1
94	Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,. <i>Blood</i> , 2011, 118, 3985-3985.	1.4	1
95	Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011, 118, 4127-4127.	1.4	9
96	Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients. <i>Blood</i> , 2011, 118, 5070-5070.	1.4	1
97	Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2). <i>Blood</i> , 2011, 118, 814-814.	1.4	13
98	The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,. <i>Blood</i> , 2011, 118, 4065-4065.	1.4	0
99	Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma. <i>Blood</i> , 2011, 118, 2909-2909.	1.4	0
100	A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 5129-5129.	1.4	0
101	â€œShort Courseâ€•Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 70-77.	2.0	7
102	Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 1955-1955.	1.4	5
103	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. <i>Blood</i> , 2010, 116, 3523-3523.	1.4	0
104	Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies. <i>Blood</i> , 2010, 116, 3541-3541.	1.4	0
105	Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.. <i>Blood</i> , 2009, 114, 306-306.	1.4	6
106	Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity.. <i>Blood</i> , 2009, 114, 746-746.	1.4	10
107	Gene Expression Profiling Reveals 5-Azacytidine to Be a Novel, Potentially Effective Therapy for Poor-Prognosis Patients with Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1833-1833.	1.4	0
108	Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 342-342.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study. <i>Blood</i> , 2008, 112, 93-93.	1.4	16
110	Total Body Irradiation 1350cGy/Fludarabine (TBI/FLU) vs Myeloablative Busulfan/Fludarabine (Bu/Flu) Preparation in Adult Recipients of Dual Umbilical Cord Blood (UCB) Transplantation: Superior Engraftment with Low Treatment-Related Mortality. <i>Blood</i> , 2008, 112, 4403-4403.	1.4	0
111	Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.. <i>Blood</i> , 2008, 112, 3325-3325.	1.4	0
112	Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.. <i>Blood</i> , 2008, 112, 2180-2180.	1.4	0
113	Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients.. <i>Blood</i> , 2007, 110, 2007-2007.	1.4	1
114	Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning: Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.. <i>Blood</i> , 2006, 108, 5399-5399.	1.4	1
115	A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.. <i>Blood</i> , 2005, 106, 5181-5181.	1.4	1
116	Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.. <i>Blood</i> , 2005, 106, 2896-2896.	1.4	5
117	Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.. <i>Blood</i> , 2005, 106, 5501-5501.	1.4	0
118	Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.. <i>Blood</i> , 2005, 106, 4623-4623.	1.4	0
119	Stem Cell Transplantation for Multiple Myeloma. <i>Cancer Control</i> , 2004, 11, 119-129.	1.8	11
120	Campath-1H May Have Activity in the Treatment of Multiple Myeloma.. <i>Blood</i> , 2004, 104, 4931-4931.	1.4	1
121	MOBILIZATION OF DENDRITIC CELLS FROM PATIENTS WITH BREAST CANCER INTO PERIPHERAL BLOOD STEM CELL LEUKAPHERESIS SAMPLES USING Flt-3-LIGAND AND G-CSF OR GM-CSF. <i>Cytokine</i> , 2002, 18, 8-19.	3.2	24